RedChip

Graphex Group (NYSE American: GRFX) is a global leader in the mid-stream deep processing of natural spherical graphite and graphene-related products, key components of the Lithium-ion (Li-ion) batteries used in Electric Vehicles (EVs), renewable energy storage systems, and other use cases. With over a decade of production experience operating at commercial-scale volumes and quality, Graphex is currently producing over 10,000 metric tons of specialized spherical graphite anode materially annually and holds patents in areas including products, production methods, machinery design, and environmental protection. With a strategy to expand its operations to support energy transition and electrification efforts worldwide, Graphex is uniquely positioned at a foundational level to grow with the industry. Visit GRFXinfo.com to learn more.

Genetic Technologies (NASDAQ: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. Visit GeneticTechInfo.com to learn more.

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases with unmet medical needs. The Company's primary focus is on its Specialized BioTherapeutics business segment, which is responsible for the development of HyBryte™, a novel photodynamic therapy that uses safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The Company has successfully completed a Phase 3 study for HyBryte™ and is now negotiating a confirmatory Phase 3 pivotal study design with the US Food & Drug Administration, while also evaluating/pursuing potential HyBryte™ marketing approval ex-U.S. with the successfully completed Phase 3 study. Visit SNGXinfo.com to learn more.

This week’s episode of the RedChip Money Report includes interviews with senior executives from QYOU Media (OTCQB: QYOUF) and Graphex (NYSE American: GRFX). Visit RedChip.com to learn more.

QYOU Media (OTCQB: QYOUF) has added to the depth and breadth of its products and capabilities throughout 2022. With five active channels now in India and the addition of ChtrSocial in India and Q Studios in the US, QYOU Media is rapidly advancing its push towards driving increased audience size and strong revenue growth in 2023 and beyond. Building on a solid foundation with accelerating momentum among major advertisers, QYOU Media is ideally positioned for long-term success. Visit QYOUFinfo.com to learn more.

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases with unmet medical needs. The Company's primary focus is on its Specialized BioTherapeutics business segment, which is responsible for the development of HyBryte™, a novel photodynamic therapy that uses safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The Company has successfully completed a Phase 3 study for HyBryte™ and is now negotiating a confirmatory Phase 3 pivotal study design with the US Food & Drug Administration, while also evaluating/pursuing potential HyBryte™ marketing approval ex-U.S. with the successfully completed Phase 3 study. Visit SNGXinfo.com to learn more.

Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program. Visit LTRNinfo.com to learn more.

Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program. Visit LTRNinfo.com to learn more.

Zomedica is revolutionizing veterinary health care with a focus on addressing unmet needs through its expanding product portfolio of innovative diagnostics and medical devices designed to improve pet health as well as productivity and practice profitability for veterinarians. With modest cash burn and a strong balance sheet, including $158.5 million cash, cash equivalents, and available-for-sale securities as of September 30, 2022, Zomedica is well-positioned to fund both organic growth and acquisitions.